-

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

  • Company establishes permanent council to drive ongoing innovation guided by community feedback
  • Report outlines targeted commitments Dexcom is making to address sentiments shared by council members

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights to strengthen its technology and reinforce its leadership as the premier choice for people with diabetes, globally.

Formed in January 2026, the Dexcom Customer Advisory Council brings together a diverse group of stakeholders – people with Type 1 and Type 2 diabetes, caregivers, diabetes educators, healthcare professionals and community advocates from around the world – to create a direct and ongoing dialogue with the people who depend on Dexcom products every day.

"Dexcom has pioneered and set the global standard for continuous glucose monitoring, and we are deeply committed to continually raising that standard to meet the evolving needs of our community," said Jake Leach, president and chief executive officer of Dexcom. "This council represents our belief that the best path forward is through listening – truly hearing what's working and what isn't. We will continue to be transparent, responsive and relentless in our pursuit of earning and maintaining the trust of our users every day."

Through independent moderation by Vital Findings, council members reinforced that Dexcom remains a life-changing, essential technology that has improved millions of lives. They also identified opportunities to improve product reliability, customer service and communication, prompting six concrete commitments outlined in the report:

  1. Delivering the best possible product by continuously improving the performance of every Dexcom sensor.
  2. Making sure product replacements are easier, replacing any sensor confirmed as a product failure without limit and offering self-service ways to request replacements.
  3. Raising the bar for customer service, making the experience more human, informed and responsive.
  4. Making the Customer Advisory Council a permanent part of how Dexcom does business.
  5. Communicating more clearly and transparently, including product updates, company news and issues (good or bad).
  6. Creating a new content series that demystifies the science and technology behind CGM.

The council will continue to meet throughout 2026, with regular public updates on progress against commitments. The full Customer Advisory Council Community Commitment Report, including in-depth discussions on accuracy, connectivity, adhesives and more, is available at dexcom.com/about-dexcom.

Toward the end of 2026, Dexcom will announce the format and approach for the continuation of the Customer Advisory Council in 2027 and beyond.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

1 Dexcom, Data on File, 2025

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com
(959) 716-6698

Dexcom

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com
(959) 716-6698

More News From Dexcom

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi...

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...
Back to Newsroom